Standard Chartered still sees bitcoin hitting $500,000 despite recent selloff

Standard Chartered still sees bitcoin hitting 0,000 despite recent selloff


Jakub Porzycki | Nurphoto | Getty Images

Standard Chartered’s bullish crypto analyst still sees bitcoin’s price hitting $500,000 during Donald Trump’s presidency — even after a selloff that sank the world’s largest digital currency to a three-month low.

Geoffrey Kendrick, who heads up digital assets research at Standard Chartered, told CNBC he believes bitcoin will hit the $200,000 mark this year before climbing even further in the coming years.

“Within the crypto ecosystem, what we need are traditional financial players, like Standard Chartered, like BlackRock and others that have the ETFs now to really step in,” Kendrick said in an interview with CNBC’s “Squawk Box Europe” Thursday.

“As the industry becomes more institutionalized, it should be safer,” Kendrick said, adding that this should result in fewer negative headlines — such as the recent $1.5 billion hack on cryptocurrency exchange Bybit last week.

This increase in crypto adoption by institutions, coupled with some “regulatory clarity” in the U.S., should lead to less volatility over time, he added.

Bitcoin to hit $500,000 before Trump leaves office, Standard Chartered says

“That should add to that medium term, top-side potential, which for me is bitcoin up to $200,000 this year, and $500,000 before Trump leaves office,” Kendrick told CNBC.

Kendrick said the catalyst necessary for large financial institutions to gain confidence to invest in bitcoin and other crypto assets is a stabilization in prices and increased regulatory clarity.

Bitcoin earlier this week sank to a three-month low below $90,000 amid declines in global equity markets. As of Thursday, the token was trading at $86,418. That means it’s down about 20% from an all-time high of $108,786, which the coin peaked at in January, according to CoinGecko data.

Standard Chartered’s Kendrick said digital currencies have dropped more broadly due to uncertainty around tariffs and resolutions to major wars such as Russia-Ukraine and Israel-Gaza.

“Risk assets don’t like uncertainty, and so that’s what we’ve seen. We’ve seen tech stocks in the U.S. coming lower,” Kendrick said, adding that the breach of Bybit has also contributed to negative sentiment surrounding crypto more broadly.

He expects the outlook for crypto will improve later in the year as traders await key regulatory developments in the industry, such as new rules around stablecoins and anti-money laundering.

“That should further legitimize, so you’ll see more U.S. banks involved. You’ll see larger institutions in the U.S. continue to push through,” Kendrick said.

Kendrick was one of the numerous market analysts who predicted a doubling in bitcoin’s price this year to $200,000. Bitcoin broke the highly anticipated $100,000 mark in December following Trump’s election to the U.S. presidency.

Crypto bulls view Trump positively given his support for digital currencies. In January, Trump signed an executive order promoting the advancement of cryptocurrencies in the U.S. and developing a national digital asset stockpile.

Crypto investors, companies and executives accounted for almost half of corporate donations in the 2024 election cycle, with some contributing tens of millions of dollars to Trump’s campaign.



Source

PayPal beats on earnings, raises full-year outlook as Venmo growth accelerates
World

PayPal beats on earnings, raises full-year outlook as Venmo growth accelerates

PayPal reported better-than-expected results for the second quarter and raised its full-year guidance for transaction margin dollars and earnings per share. The stock slipped more than 4% following the report. Here’s how the company did compared with Wall Street estimates, based on a survey of analysts by LSEG: Earnings per share: $1.40 adjusted vs. $1.30 expected […]

Read More
Novo Nordisk shares plunge 17% after Wegovy-maker cuts full-year guidance
World

Novo Nordisk shares plunge 17% after Wegovy-maker cuts full-year guidance

Medical bottles and a syringe are seen with the Novo Nordisk logo displayed on a screen in the background. Nurphoto | Nurphoto | Getty Images Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth expectations for its Wegovy obesity drug in the key U.S. market. Shares were […]

Read More
Pharma giants push for tariff clarity as ambiguity threatens EU-U.S. deal
World

Pharma giants push for tariff clarity as ambiguity threatens EU-U.S. deal

Shelf of pharmaceutical products. D3sign | Moment | Getty Images Pharma firms are calling for clarity on tariffs imposed under the new U.S.-EU trade agreement, as analysts warn that punitive sector-specific levies could risk blowing up the entire deal. Ambiguity abounds around the terms for pharmaceutical goods under the trade truce agreed Sunday, which imposes […]

Read More